Repertoire Immune Medicines is a clinical-stage biotechnology company developing medicines that harness the human immune system to prevent or treat disease. Its work focuses on cancer and autoimmune conditions, with the company also describing its broader mission as addressing infectious diseases. Repertoire aims to identify distinctive patterns, or “codes,” in the body’s T cell repertoire and the interactions that guide immune responses, then use these insights to create programmable immune medicines.

The company’s proprietary DECODE platform studies the immune synapse, a central component of the adaptive immune system. By seeking to understand how immune cells recognize and respond to disease, Repertoire uses the platform to inform the design and development of targeted therapies. Its research includes approaches intended for solid and hematological cancers, as well as efforts to generate a new class of medicines for people with autoimmune diseases.

Repertoire maintains a development pipeline and reports clinical-stage programs, including investigational medicine RPTR-1-201, which received FDA Fast Track designation according to the company’s May 2026 news announcement.